Recent progress in therapeutic strategies for ischemic stroke

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Possible strategies for treating stroke include neuroprotection in the acute phase of cerebral ischemia and stem cell therapy in the chronic phase of cerebral ischemia. Previously, we have studied the temporal and spatial expression patterns of c-fos, hypoxia inducible factor-1a (HIF-1a), heat shock protein 70 (HSP70), and annexin V after 90 min of transient middle cerebral occlusion in rats and concluded that there is a time window for neuroprotection from 12 to 48 h after ischemia. In addition, we have estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by injecting Sendai viral vector containing the GDNF gene into the postischemic brain. This Sendai virus-mediated gene transfer of GDNF showed a significant neuroprotective effect in the ischemic brain. Additionally, we have administered GDNF and hepatocyte growth factor (HGF) protein into the postischemic rat brain and estimated the infarct size and antiapoptotic and antiautophagic effects. GDNF and HGF significantly reduced infarct size, the number of microtubuleassociated protein 1 light chain 3 (LC3)-positive cells, and the number of terminal deoxynucleotidyl transferasemediated dUTP-biotin in situ nick-end labeling (TUNEL)-positive cells, indicating that GDNF and HGF were greatly associated with not only the antiapoptotic effect but also the antiautophagic effects. Finally, we have previously transplanted undifferentiated iPSCs into the ipsilateral striatum and cortex at 24 h after cerebral ischemia. Histological analysis was performed at 14 and 28 days after cell transplantation, and we found that iPSCs could supply a great number of doublecortin-positive neuroblasts but also formed tridermal teratoma in the ischemic brain. Our results suggest that iPSCs have a potential to provide neural cells after ischemic brain injury if tumorigenesis is properly controlled. In the future, we will combine these strategies to develop more effective therapies for the treatment of strokes.

Original languageEnglish
Article number6
Pages (from-to)893-898
Number of pages6
JournalCell Transplantation
Volume25
Issue number5
DOIs
Publication statusPublished - 2016

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Stroke
Brain
Hepatocyte Growth Factor
Brain Ischemia
In Situ Nick-End Labeling
Neuroprotective Agents
Proteins
Rats
Therapeutics
Cells
Gene transfer
Sendai virus
HSP70 Heat-Shock Proteins
Annexin A5
Teratoma
Cell Transplantation
Biotin
Cell- and Tissue-Based Therapy
Stem cells

Keywords

  • Cell transplantation
  • Induced pluripotent stem cells (iPSCs)
  • Multiple molecular penumbra
  • Neurotrophic factor

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering

Cite this

Recent progress in therapeutic strategies for ischemic stroke. / Yamashita, Toru; Abe, Koji.

In: Cell Transplantation, Vol. 25, No. 5, 6, 2016, p. 893-898.

Research output: Contribution to journalArticle

@article{9ef62b00ab664d2498dec89c5430c028,
title = "Recent progress in therapeutic strategies for ischemic stroke",
abstract = "Possible strategies for treating stroke include neuroprotection in the acute phase of cerebral ischemia and stem cell therapy in the chronic phase of cerebral ischemia. Previously, we have studied the temporal and spatial expression patterns of c-fos, hypoxia inducible factor-1a (HIF-1a), heat shock protein 70 (HSP70), and annexin V after 90 min of transient middle cerebral occlusion in rats and concluded that there is a time window for neuroprotection from 12 to 48 h after ischemia. In addition, we have estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by injecting Sendai viral vector containing the GDNF gene into the postischemic brain. This Sendai virus-mediated gene transfer of GDNF showed a significant neuroprotective effect in the ischemic brain. Additionally, we have administered GDNF and hepatocyte growth factor (HGF) protein into the postischemic rat brain and estimated the infarct size and antiapoptotic and antiautophagic effects. GDNF and HGF significantly reduced infarct size, the number of microtubuleassociated protein 1 light chain 3 (LC3)-positive cells, and the number of terminal deoxynucleotidyl transferasemediated dUTP-biotin in situ nick-end labeling (TUNEL)-positive cells, indicating that GDNF and HGF were greatly associated with not only the antiapoptotic effect but also the antiautophagic effects. Finally, we have previously transplanted undifferentiated iPSCs into the ipsilateral striatum and cortex at 24 h after cerebral ischemia. Histological analysis was performed at 14 and 28 days after cell transplantation, and we found that iPSCs could supply a great number of doublecortin-positive neuroblasts but also formed tridermal teratoma in the ischemic brain. Our results suggest that iPSCs have a potential to provide neural cells after ischemic brain injury if tumorigenesis is properly controlled. In the future, we will combine these strategies to develop more effective therapies for the treatment of strokes.",
keywords = "Cell transplantation, Induced pluripotent stem cells (iPSCs), Multiple molecular penumbra, Neurotrophic factor",
author = "Toru Yamashita and Koji Abe",
year = "2016",
doi = "10.3727/096368916X690548",
language = "English",
volume = "25",
pages = "893--898",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "5",

}

TY - JOUR

T1 - Recent progress in therapeutic strategies for ischemic stroke

AU - Yamashita, Toru

AU - Abe, Koji

PY - 2016

Y1 - 2016

N2 - Possible strategies for treating stroke include neuroprotection in the acute phase of cerebral ischemia and stem cell therapy in the chronic phase of cerebral ischemia. Previously, we have studied the temporal and spatial expression patterns of c-fos, hypoxia inducible factor-1a (HIF-1a), heat shock protein 70 (HSP70), and annexin V after 90 min of transient middle cerebral occlusion in rats and concluded that there is a time window for neuroprotection from 12 to 48 h after ischemia. In addition, we have estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by injecting Sendai viral vector containing the GDNF gene into the postischemic brain. This Sendai virus-mediated gene transfer of GDNF showed a significant neuroprotective effect in the ischemic brain. Additionally, we have administered GDNF and hepatocyte growth factor (HGF) protein into the postischemic rat brain and estimated the infarct size and antiapoptotic and antiautophagic effects. GDNF and HGF significantly reduced infarct size, the number of microtubuleassociated protein 1 light chain 3 (LC3)-positive cells, and the number of terminal deoxynucleotidyl transferasemediated dUTP-biotin in situ nick-end labeling (TUNEL)-positive cells, indicating that GDNF and HGF were greatly associated with not only the antiapoptotic effect but also the antiautophagic effects. Finally, we have previously transplanted undifferentiated iPSCs into the ipsilateral striatum and cortex at 24 h after cerebral ischemia. Histological analysis was performed at 14 and 28 days after cell transplantation, and we found that iPSCs could supply a great number of doublecortin-positive neuroblasts but also formed tridermal teratoma in the ischemic brain. Our results suggest that iPSCs have a potential to provide neural cells after ischemic brain injury if tumorigenesis is properly controlled. In the future, we will combine these strategies to develop more effective therapies for the treatment of strokes.

AB - Possible strategies for treating stroke include neuroprotection in the acute phase of cerebral ischemia and stem cell therapy in the chronic phase of cerebral ischemia. Previously, we have studied the temporal and spatial expression patterns of c-fos, hypoxia inducible factor-1a (HIF-1a), heat shock protein 70 (HSP70), and annexin V after 90 min of transient middle cerebral occlusion in rats and concluded that there is a time window for neuroprotection from 12 to 48 h after ischemia. In addition, we have estimated the neuroprotective effect of glial cell line-derived neurotrophic factor (GDNF) by injecting Sendai viral vector containing the GDNF gene into the postischemic brain. This Sendai virus-mediated gene transfer of GDNF showed a significant neuroprotective effect in the ischemic brain. Additionally, we have administered GDNF and hepatocyte growth factor (HGF) protein into the postischemic rat brain and estimated the infarct size and antiapoptotic and antiautophagic effects. GDNF and HGF significantly reduced infarct size, the number of microtubuleassociated protein 1 light chain 3 (LC3)-positive cells, and the number of terminal deoxynucleotidyl transferasemediated dUTP-biotin in situ nick-end labeling (TUNEL)-positive cells, indicating that GDNF and HGF were greatly associated with not only the antiapoptotic effect but also the antiautophagic effects. Finally, we have previously transplanted undifferentiated iPSCs into the ipsilateral striatum and cortex at 24 h after cerebral ischemia. Histological analysis was performed at 14 and 28 days after cell transplantation, and we found that iPSCs could supply a great number of doublecortin-positive neuroblasts but also formed tridermal teratoma in the ischemic brain. Our results suggest that iPSCs have a potential to provide neural cells after ischemic brain injury if tumorigenesis is properly controlled. In the future, we will combine these strategies to develop more effective therapies for the treatment of strokes.

KW - Cell transplantation

KW - Induced pluripotent stem cells (iPSCs)

KW - Multiple molecular penumbra

KW - Neurotrophic factor

UR - http://www.scopus.com/inward/record.url?scp=84964252982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964252982&partnerID=8YFLogxK

U2 - 10.3727/096368916X690548

DO - 10.3727/096368916X690548

M3 - Article

C2 - 26786838

AN - SCOPUS:84964252982

VL - 25

SP - 893

EP - 898

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 5

M1 - 6

ER -